Dosage: Determined solely by the prescribing healthcare provider. Dosing typically follows a gradual titration schedule beginning at a low initiation dose, with increases at regular intervals based on individual response and tolerability. Do not adjust your dose without explicit guidance from your provider.

Typical titration approach (as determined by prescriber):

Weeks 1–4: 0.25 mg semaglutide once weekly (initiation dose)

Weeks 5–8: 0.5 mg once weekly

Weeks 9+: Further escalation to 1 mg or 2 mg as indicated, at the prescriber's discretion

Route of administration: Subcutaneous injection only. Recommended sites include the abdomen (avoiding the area immediately around the navel), the anterior thigh, or the outer upper arm. Rotate injection sites with each weekly dose. Do not inject into areas that are bruised, tender, scarred, or irritated.

Injection timing: Once weekly, on the same day each week. The injection may be administered at any time of day, with or without food. Consistency of timing helps maintain stable drug levels.

Missed doses: If a dose is missed, administer it as soon as possible if within five days of the scheduled date. If more than five days have passed, skip the missed dose and resume on the next regularly scheduled day. Never administer two doses within three days of each other to compensate for a missed injection.

This medication should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is contraindicated in patients with known hypersensitivity to semaglutide, cyanocobalamin, or any component of the formulation. Patients with Leber's hereditary optic neuropathy should not receive cyanocobalamin-containing preparations without specialist evaluation, as the cyanocobalamin form of B12 may be inappropriate for this condition. This medication is contraindicated during pregnancy.

Patients with a history of pancreatitis, severe gastroparesis, significant gastrointestinal disorders, severe renal impairment, or serious hepatic dysfunction should discuss individual suitability with their prescriber before initiating therapy.

Common side effects are predominantly gastrointestinal and are most frequent during dose escalation. These include nausea, vomiting, diarrhea, constipation, abdominal discomfort, reduced appetite, and dyspepsia. Most patients find that these effects diminish as their body adjusts to each dose level. Eating smaller meals, avoiding high-fat or spicy foods, and staying well hydrated can help manage these symptoms during titration.

Injection site reactions — including localized redness, mild swelling, or brief discomfort — may occur and generally resolve within a few days. Rotating injection sites consistently helps minimize recurrence.

Hypoglycemia risk is low when semaglutide is used alone, due to its glucose-dependent mechanism. However, concurrent use with insulin or sulfonylureas significantly increases hypoglycemia risk, and dose reductions of those agents are often needed when semaglutide is initiated. Patients should monitor blood glucose as directed by their provider.

Serious adverse effects requiring prompt medical attention include severe or persistent abdominal pain (which may indicate pancreatitis), right upper quadrant pain or jaundice (which may indicate gallbladder disease), signs of allergic reaction (rash, swelling, difficulty breathing), and any significant vision changes. Patients with pre-existing diabetic retinopathy should be monitored ophthalmologically during treatment, as rapid improvements in glycemic control may transiently affect retinal status.

Psychiatric symptoms: Post-marketing reports have described mood changes and suicidal ideation in patients using GLP-1 receptor agonists. A causal relationship has not been established, but patients with a history of depression or other psychiatric conditions should be monitored for behavioral changes, particularly early in treatment.

Drug interactions to discuss with your provider: Oral contraceptives (absorption timing may be affected by slowed gastric emptying), warfarin (INR monitoring may need to increase), levothyroxine (absorption may be affected), metformin (may reduce B12 absorption over time, making the cyanocobalamin component particularly relevant), and any other glucose-lowering agents.

This medication is not recommended during pregnancy. Animal studies have shown embryofetal toxicity at relevant exposures, and adequate human safety data is not available. Women of reproductive potential should use effective contraception during treatment. If pregnancy occurs while using this medication, contact your healthcare provider immediately. Due to semaglutide's extended half-life, discontinuation at least two months prior to a planned pregnancy is generally recommended. Consult your provider regarding use during breastfeeding.

Store refrigerated at 36°F–46°F (2°C–8°C). Cyanocobalamin is light-sensitive — keep the vial in its original packaging or in a light-protected location when not in use. Do not freeze; freezing causes irreversible structural damage to semaglutide and must be strictly avoided. Do not store near the freezer compartment or in refrigerator door shelves where temperature fluctuations are more pronounced.

Before each use, visually inspect the solution. It should appear clear to slightly amber-colored and free of particulates. Do not use the vial if the solution appears cloudy, discolored, or contains visible particles.

Once a multi-dose vial has been accessed, record the date of first use on the label and discard after 28 days regardless of remaining volume. When traveling, use an insulated carrier with ice packs — take care to prevent direct contact between the vial and ice to avoid freezing. Never store in a vehicle or any environment where temperatures may exceed safe limits.

Dispose of unused or expired medication through a pharmaceutical take-back program or in accordance with your pharmacy's disposal guidance. Do not flush down drains or dispose of in household waste.